Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.17% $58.70
America/New_York / 22 jan 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 4 117.67 mill |
EPS: | -12.18 |
P/E: | -4.82 |
Earnings Date: | Feb 26, 2024 |
SharesOutstanding: | 70.15 mill |
Avg Daily Volume: | 1.779 mill |
RATING 2024-01-22 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.82 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.82x |
Company: PE -4.82 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 58.22 - 59.19 ( +/- 0.83%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-23 | Boxer Capital, Llc | Sell | 30 518 | Common Stock |
2024-01-23 | Boxer Capital, Llc | Sell | 1 413 475 | Warrant (right to purchase) |
2024-01-23 | Sharp Shalini | Sell | 4 162 | Common Stock |
2024-01-23 | Sharp Shalini | Sell | 5 252 | Common Stock |
2024-01-23 | Sharp Shalini | Sell | 6 808 | Common Stock |
INSIDER POWER |
---|
-93.84 |
Last 100 transactions |
Buy: 125 442 | Sell: 3 801 194 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $58.70 (-0.17% ) |
Volume | 20.96 mill |
Avg. Vol. | 1.779 mill |
% of Avg. Vol | 1 178.27 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.